Skip to content

PLOS is a non-profit organization on a mission to drive open science forward with measurable, meaningful change in research publishing, policy, and practice.

Building on a strong legacy of pioneering innovation, PLOS continues to be a catalyst, reimagining models to meet open science principles, removing barriers and promoting inclusion in knowledge creation and sharing, and publishing research outputs that enable everyone to learn from, reuse and build upon scientific knowledge.

We believe in a better future where science is open to all, for all.

Medicine & Health

Flubendazole in Onchocerciasis

Partnered Collections, Special Issues

Treating onchocerciasis remains a challenge as no drug effectively kills the adult worms. A new orally bioavailable formulation of flubendazole was developed and tested to find out whether it could be a safe and effective macrofilaricidal drug. The introduction to this collection explains the history and rationale for development. The subsequent 3 articles report on the efficacy, PK and safety as observed in animal models. The last article summarizes the toxicology and preclinical PK data generated with this new flubendazole formulation. It also explains that the decision to discontinue its development was taken because no safe and effective dose could be selected for use in clinical trials.

Image Credit: International Centre for Eye Health, London School of Hygiene & Tropical Medicine.

Introduction
Preclinical efficacy of flubendazole in antifilarial animal models
Preclinical toxicology and pharmacokinetics of a new oral flubendazole formulation
PLOS Biologue

Loading...

Back to top